In KRAS G12C-mutated NSCLC, SMARCA4 co-mutations occurred in approximately 10% of cases,4,61 and confer a clearly detrimental impact on KRAS G12Ci and immunotherapy outcomes. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.